UAE Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.
UAE Soft Tissue Sarcoma Market is valued at around $18.5 Mn in 2022 and is projected to reach $36.6 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period 2023-2030.
Soft tissue sarcoma (STS) refers to a group of rare cancers that develop in the soft tissues of the body, such as muscles, tendons, fat, and blood vessels. There are about 50 different kinds of soft tissue sarcoma, including rhabdomyosarcoma, clear cell sarcoma, malignant mesenchymal, alveolar soft-part sarcoma, adult fibrosarcoma, and angiosarcoma. Sunitinib (Sutent), trabectedin (Yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and other medications are used to treat soft tissue sarcomas. However, these tumours have a diverse range of characteristics, making diagnosis quite difficult. Chemotherapy drugs like Doxorubicin, Ifosfamide and gemcitabine. Targeted therapies like pazopanib, Imatinib and immunotherapy like pembrolizumab are commonly used for treatment. Chemotherapy currently has the highest market share. Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India) are the key global market players.
Market Drivers
Increasing prevalence and incidence of soft tissue sarcoma, raising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics all act as market growth drivers.
Market Restraints
Side-Effects of Soft Tissue Sarcoma Drugs like swelling under the skin, tummy, mouth sores, fatigue and nausea act as market growth restraints.
High costs of treatment also act as a market growth restraint.
Notable deals in the Soft Tissue Sarcoma market
In June 2021 Johnson & Johnson declared that the US Food and Drug Administration had authorised JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is being developed for use in the treatment of several malignancies, including some types of sarcoma, even though it is not specifically for the treatment of soft tissue sarcoma.
In Jan 2021: Pfizer stated that the European Commission had approved Vitrakvi (larotrectinib) for the treatment of advanced soft tissue sarcoma.
Key players
Pfizer Johnson & Johnson Novartis Roche AbbVie Amgen Celgene Gilead Sciences Seattle Genetics Merck1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Disease Type
By Treatment Type
By Route of Administration
By End-Users
By Distribution Channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.